153 related articles for article (PubMed ID: 20562912)
21. Rho-kinase inhibitor upregulates migration by altering focal adhesion formation via the Akt pathway in colon cancer cells.
Adachi S; Yasuda I; Nakashima M; Yamauchi T; Yoshioka T; Okano Y; Moriwaki H; Kozawa O
Eur J Pharmacol; 2011 Jan; 650(1):145-50. PubMed ID: 20959118
[TBL] [Abstract][Full Text] [Related]
22. Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor.
Sakai K; Arao T; Shimoyama T; Murofushi K; Sekijima M; Kaji N; Tamura T; Saijo N; Nishio K
FASEB J; 2006 Feb; 20(2):311-3. PubMed ID: 16373402
[TBL] [Abstract][Full Text] [Related]
23. Icotinib, a potent and specific EGFR tyrosine kinase inhibitor, inhibits growth of squamous cell carcinoma cell line A431 through negatively regulating AKT signaling.
Gao Z; Chen W; Zhang X; Cai P; Fang X; Xu Q; Sun Y; Gu Y
Biomed Pharmacother; 2013 Jun; 67(5):351-6. PubMed ID: 23602321
[TBL] [Abstract][Full Text] [Related]
24. Rho/ROCK pathway as a target of tumor therapy.
Rattan R; Giri S; Singh AK; Singh I
J Neurosci Res; 2006 Feb; 83(2):243-55. PubMed ID: 16385577
[TBL] [Abstract][Full Text] [Related]
25. Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.
Rojo F; Gracias E; Villena N; Cruz T; Corominas JM; Corradino I; Cedeño M; Campas C; Osorio M; Iznaga N; Bellosillo B; Rovira A; Marsoni S; Gascon P; Serrano S; Sessa C; Crombet T; Albanell J
Clin Cancer Res; 2010 Apr; 16(8):2474-82. PubMed ID: 20371675
[TBL] [Abstract][Full Text] [Related]
26. The role of geranylgeranylated proteins in human mesangial cell proliferation.
Khwaja A; Sharpe CC; Noor M; Hendry BM
Kidney Int; 2006 Oct; 70(7):1296-304. PubMed ID: 16929252
[TBL] [Abstract][Full Text] [Related]
27. Lovastatin inhibits VEGFR and AKT activation: synergistic cytotoxicity in combination with VEGFR inhibitors.
Zhao TT; Trinh D; Addison CL; Dimitroulakos J
PLoS One; 2010 Sep; 5(9):e12563. PubMed ID: 20838437
[TBL] [Abstract][Full Text] [Related]
28. Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.
Jacobsen K; Bertran-Alamillo J; Molina MA; Teixidó C; Karachaliou N; Pedersen MH; Castellví J; Garzón M; Codony-Servat C; Codony-Servat J; Giménez-Capitán A; Drozdowskyj A; Viteri S; Larsen MR; Lassen U; Felip E; Bivona TG; Ditzel HJ; Rosell R
Nat Commun; 2017 Sep; 8(1):410. PubMed ID: 28871105
[TBL] [Abstract][Full Text] [Related]
29. Salinomycin acts through reducing AKT-dependent thymidylate synthase expression to enhance erlotinib-induced cytotoxicity in human lung cancer cells.
Tung CL; Chen JC; Wu CH; Peng YS; Chen WC; Zheng HY; Jian YJ; Wei CL; Cheng YT; Lin YW
Exp Cell Res; 2017 Aug; 357(1):59-66. PubMed ID: 28454878
[TBL] [Abstract][Full Text] [Related]
30. Lovastatin-induced apoptosis is mediated by activating transcription factor 3 and enhanced in combination with salubrinal.
Niknejad N; Gorn-Hondermann I; Ma L; Zahr S; Johnson-Obeseki S; Corsten M; Dimitroulakos J
Int J Cancer; 2014 Jan; 134(2):268-79. PubMed ID: 23824972
[TBL] [Abstract][Full Text] [Related]
31. Significance of interleukin-6 signaling in the resistance of pharyngeal cancer to irradiation and the epidermal growth factor receptor inhibitor.
Chen CC; Chen WC; Lu CH; Wang WH; Lin PY; Lee KD; Chen MF
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1214-24. PubMed ID: 20206020
[TBL] [Abstract][Full Text] [Related]
32. Chimeric ubiquitin ligases inhibit non-small cell lung cancer via negative modulation of EGFR signaling.
Zhong D; Ru Y; Wang Q; Zhang J; Zhang J; Wei J; Wu J; Yao L; Li X; Li X
Cancer Lett; 2015 Apr; 359(1):57-64. PubMed ID: 25573345
[TBL] [Abstract][Full Text] [Related]
33. Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways.
Nölting S; Maurer J; Spöttl G; Aristizabal Prada ET; Reuther C; Young K; Korbonits M; Göke B; Grossman A; Auernhammer CJ
PLoS One; 2015; 10(12):e0143830. PubMed ID: 26636335
[TBL] [Abstract][Full Text] [Related]
34. Hyaluronan-CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase C epsilon-Ca2+ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells.
Bourguignon LY; Gilad E; Brightman A; Diedrich F; Singleton P
J Biol Chem; 2006 May; 281(20):14026-40. PubMed ID: 16565089
[TBL] [Abstract][Full Text] [Related]
35. Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of EGF-EGFR-PI3K-Akt-Erk pathway.
Zhang Y; Wang L; Zhang M; Jin M; Bai C; Wang X
J Cell Physiol; 2012 Jan; 227(1):35-43. PubMed ID: 21412767
[TBL] [Abstract][Full Text] [Related]
36. PKCε acts as negative allosteric modulator of EGF receptor signalling.
Weisheit S; Schäfer C; Mertens C; Berndt A; Liebmann C
Cell Signal; 2011 Feb; 23(2):436-48. PubMed ID: 20965248
[TBL] [Abstract][Full Text] [Related]
37. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer.
Bussink J; van der Kogel AJ; Kaanders JH
Lancet Oncol; 2008 Mar; 9(3):288-96. PubMed ID: 18308254
[TBL] [Abstract][Full Text] [Related]
38. N-acetylcysteine (NAC) inhibits cell growth by mediating the EGFR/Akt/HMG box-containing protein 1 (HBP1) signaling pathway in invasive oral cancer.
Lee MF; Chan CY; Hung HC; Chou IT; Yee AS; Huang CY
Oral Oncol; 2013 Feb; 49(2):129-35. PubMed ID: 22944050
[TBL] [Abstract][Full Text] [Related]
39. Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells.
Ma L; Niknejad N; Gorn-Hondermann I; Dayekh K; Dimitroulakos J
PLoS One; 2012; 7(9):e46055. PubMed ID: 23029387
[TBL] [Abstract][Full Text] [Related]
40. Expression of protein tyrosine kinases in head and neck squamous cell carcinomas.
Ongkeko WM; Altuna X; Weisman RA; Wang-Rodriguez J
Am J Clin Pathol; 2005 Jul; 124(1):71-6. PubMed ID: 15923166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
